×
Join our live online event
How top hedge funds use news to make money
form the stock market & how ordinary people are
copying their strategies
Register now!
form the stock market & how ordinary people are
copying their strategies
No thanks
ZLAB – zai lab limited - american depositary shares (US:NASDAQ)
DELAYED
$
| Volume Shares | |
| 1 Day Range | |
| Volume Ratio | |
| 52 Week High | |
| 52 Week Low |
| VWAP | |
| Today’s Volatility | |
| 20 Days Volatility | |
| Open | |
| Prior Close |
1D
5D
1M
3M
YTD
1Y
3Y
1 Day
ZLAB
SPY
QQQ
Swipe to see more
Main News & Impact Reports
Date
Time
Symbol
Headline
Impact
3/18
12:25 pm
zlab
Zai Lab (ZLAB) had its price target lowered by JPMorgan Chase & Co. from $39.00 to $32.00. They now have an "overweight" rating on the stock.
Low
Report
Zai Lab (ZLAB) had its price target lowered by JPMorgan Chase & Co. from $39.00 to $32.00. They now have an "overweight" rating on the stock.
3/18
11:22 am
zlab
Nationwide International Small Cap Fund Q4 2025 Commentary [Seeking Alpha]
Low
Report
Nationwide International Small Cap Fund Q4 2025 Commentary [Seeking Alpha]
3/17
05:08 pm
zlab
Zai Lab to Present New Data on Three Internally Developed Oncology Candidates at AACR 2026, Including Zocilurtatug Pelitecan, a DLL3-Targeting Antibody-Drug Conjugate (ADC) [Yahoo! Finance]
Low
Report
Zai Lab to Present New Data on Three Internally Developed Oncology Candidates at AACR 2026, Including Zocilurtatug Pelitecan, a DLL3-Targeting Antibody-Drug Conjugate (ADC) [Yahoo! Finance]
3/17
04:35 pm
zlab
Zai Lab to Present New Data on Three Internally Developed Oncology Candidates at AACR 2026, Including Zocilurtatug Pelitecan, a DLL3-Targeting Antibody-Drug Conjugate (ADC)
Low
Report
Zai Lab to Present New Data on Three Internally Developed Oncology Candidates at AACR 2026, Including Zocilurtatug Pelitecan, a DLL3-Targeting Antibody-Drug Conjugate (ADC)
3/9
05:51 pm
zlab
Neuroendocrine Carcinoma Market Poised for Significant Growth During the Forecast Period (2026-2036) Driven by Rising Incidence and Advancements in Targeted Therapies | DelveInsight [Yahoo! Finance]
Low
Report
Neuroendocrine Carcinoma Market Poised for Significant Growth During the Forecast Period (2026-2036) Driven by Rising Incidence and Advancements in Targeted Therapies | DelveInsight [Yahoo! Finance]
3/1
07:42 am
zlab
Is Zai Lab (ZLAB) Now A Bargain After Recent 15.8% Share Price Jump? [Yahoo! Finance]
Medium
Report
Is Zai Lab (ZLAB) Now A Bargain After Recent 15.8% Share Price Jump? [Yahoo! Finance]
2/27
06:28 pm
zlab
Zai Lab Q4 Earnings Call Highlights [Yahoo! Finance]
Medium
Report
Zai Lab Q4 Earnings Call Highlights [Yahoo! Finance]
2/27
09:47 am
zlab
Zai Lab (ZLAB) had its price target lowered by Cantor Fitzgerald from $55.00 to $37.00. They now have an "overweight" rating on the stock.
Low
Report
Zai Lab (ZLAB) had its price target lowered by Cantor Fitzgerald from $55.00 to $37.00. They now have an "overweight" rating on the stock.
Date
Time
Symbol
Company Name
Action
%Chg
2/26/2026
07:00 am
zlab
zai lab limited - american depositary shares
MISS
Report
2.2%
zai lab limited - american depositary shares
11/6/2025
07:00 am
zlab
zai lab limited - american depositary shares
MISS
Report
0.7%
zai lab limited - american depositary shares
8/7/2025
06:00 am
zlab
zai lab limited - american depositary shares
IN-LINE
Report
-13.6%
zai lab limited - american depositary shares
5/8/2025
06:00 am
zlab
zai lab limited - american depositary shares
BEAT
Report
1.9%
zai lab limited - american depositary shares
Date
Time
Action
From
To
Firm
Impact
%Chg
Date
Time
Symbol
Headline
Impact
3/19
04:06 pm
zlab
Form 4 Zai Lab Ltd For: Mar 17 Filed by: GAYNOR RICHARD
Low
Report
Form 4 Zai Lab Ltd For: Mar 17 Filed by: GAYNOR RICHARD
3/16
04:09 pm
zlab
Form 4 Zai Lab Ltd For: Mar 04 Filed by: Edmondson Frazor Titus III
Low
Report
Form 4 Zai Lab Ltd For: Mar 04 Filed by: Edmondson Frazor Titus III
3/16
04:09 pm
zlab
Form 4 Zai Lab Ltd For: Mar 04 Filed by: Smiley Joshua L
Low
Report
Form 4 Zai Lab Ltd For: Mar 04 Filed by: Smiley Joshua L
3/16
04:08 pm
zlab
Form 4 Zai Lab Ltd For: Mar 04 Filed by: Amado Rafael
Low
Report
Form 4 Zai Lab Ltd For: Mar 04 Filed by: Amado Rafael
3/16
04:08 pm
zlab
Form 4 Zai Lab Ltd For: Mar 04 Filed by: Chen Yajing
Low
Report
Form 4 Zai Lab Ltd For: Mar 04 Filed by: Chen Yajing
3/16
04:06 pm
zlab
Form 4 Zai Lab Ltd For: Mar 11 Filed by: Du Ying
Low
Report
Form 4 Zai Lab Ltd For: Mar 11 Filed by: Du Ying
3/13
04:04 pm
zlab
Form 144 Zai Lab Ltd Filed by: Edmondson Frazor Titus III
Medium
Report
Form 144 Zai Lab Ltd Filed by: Edmondson Frazor Titus III
3/13
03:50 pm
zlab
Form 144 Zai Lab Ltd Filed by: Smiley Joshua L
Low
Report
Form 144 Zai Lab Ltd Filed by: Smiley Joshua L
Stock Stats
| News Stats | |
|---|---|
| All News | |
| News Wires | |
| Media Monitoring | |
| SEC Edgar Filings | |
| Upgrades | |
| Downgrades | |
| Initiated | |
| Reiterated | |
| Last Earnings | |
| Last Earnings EPS | |
| Next Earnings | |
| Order Stats |
|---|
| Sub-Penny |
|
|
| Odd lot |
|
|
| Avg. bid-ask spread |
|
|
| Avg. bid-ask size |
|
|
| Shares at ask/bid |
|
|
| Off exchange |
|
|
Main News & Impact Reports
TOP News Gainers
1/23
Form 6-K Zai Lab Ltd For: Jan 22
14.5%
10/30 Zai Lab Announces Upcoming Presentations at November Conferences 12.5%
1/14 Zai Lab Appoints Lonnie Moulder to Board of Directors 9.3%
9/4 Zai Lab Ltd (NASDAQ: ZLAB) is now covered by analysts at China Renaissance Securities Ltd.. They set a "buy" rating on the stock. 6.7%
5/6 Form 424B2 Zai Lab Ltd 5.5%
12/27 Zai Lab Announces NMPA Approval of ZEJULA® (Niraparib) in China as Maintenance Therapy for Patients with Recurrent Ovarian Cancer 5.3%
10/25 Zai Lab Partner, MacroGenics, Announces Initiation of Phase 2/3 MAHOGANY Study of Margetuximab in Gastric or Gastroesophageal Junction Cancer 5.2%
1/12 Week In Review: 4 China Biopharmas Announce $100+ Million Deals In First Week Of 2020 [Seeking Alpha] 5.0%
4/8 Regeneron and Zai Lab Announce Regional Strategic Collaboration for REGN1979 (CD20xCD3 Bispecific Antibody) 5.0%
2/10 Zai Lab Announces Acceptance of NDA Submission of Omadacycline in China by the NMPA 5.0%
10/30 Zai Lab Announces Upcoming Presentations at November Conferences 12.5%
1/14 Zai Lab Appoints Lonnie Moulder to Board of Directors 9.3%
9/4 Zai Lab Ltd (NASDAQ: ZLAB) is now covered by analysts at China Renaissance Securities Ltd.. They set a "buy" rating on the stock. 6.7%
5/6 Form 424B2 Zai Lab Ltd 5.5%
12/27 Zai Lab Announces NMPA Approval of ZEJULA® (Niraparib) in China as Maintenance Therapy for Patients with Recurrent Ovarian Cancer 5.3%
10/25 Zai Lab Partner, MacroGenics, Announces Initiation of Phase 2/3 MAHOGANY Study of Margetuximab in Gastric or Gastroesophageal Junction Cancer 5.2%
1/12 Week In Review: 4 China Biopharmas Announce $100+ Million Deals In First Week Of 2020 [Seeking Alpha] 5.0%
4/8 Regeneron and Zai Lab Announce Regional Strategic Collaboration for REGN1979 (CD20xCD3 Bispecific Antibody) 5.0%
2/10 Zai Lab Announces Acceptance of NDA Submission of Omadacycline in China by the NMPA 5.0%
TOP News Decliners
3/16
Form 6-K Zai Lab Ltd For: Mar 16
-12.6%
8/27 Zai Lab Ltd (NASDAQ: ZLAB) was upgraded by analysts at BidaskClub from a "hold" rating to a "buy" rating. -7.4%
12/16 Zai Lab Announces the Appointment of Timothy Yap, M.D., Ph.D., to its Scientific Advisory Board -6.0%
1/21 Form POSASR Zai Lab Ltd -5.8%
5/16 Zai Lab Announces CTA Approval to Initiate a Phase 3 Clinical Trial of ETX2514SUL for the Treatment of Carbapenem-Resistant Acinetobacter Infections -4.8%
4/30 Zai Lab Announces Upcoming Participation in the BofA Securities 2020 Health Care Conference -4.5%
8/12 China National Medical Products Administration Grants Innovative Medical Device Designation for Optune® in China -3.7%
3/19 Zai Lab's (ZLAB) CEO Samantha Du on Q4 2019 Results - Earnings Call Transcript [Seeking Alpha] -3.2%
6/28 Zai Lab Ltd (NASDAQ: ZLAB) was upgraded by analysts at BidaskClub from a "buy" rating to a "strong-buy" rating. -2.6%
4/27 Zai Lab Ltd (NASDAQ: ZLAB) is now covered by analysts at Goldman Sachs Group Inc. They set a "buy" rating on the stock. -2.1%
8/27 Zai Lab Ltd (NASDAQ: ZLAB) was upgraded by analysts at BidaskClub from a "hold" rating to a "buy" rating. -7.4%
12/16 Zai Lab Announces the Appointment of Timothy Yap, M.D., Ph.D., to its Scientific Advisory Board -6.0%
1/21 Form POSASR Zai Lab Ltd -5.8%
5/16 Zai Lab Announces CTA Approval to Initiate a Phase 3 Clinical Trial of ETX2514SUL for the Treatment of Carbapenem-Resistant Acinetobacter Infections -4.8%
4/30 Zai Lab Announces Upcoming Participation in the BofA Securities 2020 Health Care Conference -4.5%
8/12 China National Medical Products Administration Grants Innovative Medical Device Designation for Optune® in China -3.7%
3/19 Zai Lab's (ZLAB) CEO Samantha Du on Q4 2019 Results - Earnings Call Transcript [Seeking Alpha] -3.2%
6/28 Zai Lab Ltd (NASDAQ: ZLAB) was upgraded by analysts at BidaskClub from a "buy" rating to a "strong-buy" rating. -2.6%
4/27 Zai Lab Ltd (NASDAQ: ZLAB) is now covered by analysts at Goldman Sachs Group Inc. They set a "buy" rating on the stock. -2.1%
Don’t Miss Out On The Next BIG Stock Move
Never get left behind with our daily ‘Shakers & Movers’ newsletter. Discover the biggest gainer or loser in the stock market, and learn exactly WHY it moved. To find out which one caught Wall Street by surprise TODAY, sign up to our newsletter below: